reMYND CRO

Booth 1664
Leuven, Belgium
Our Contract Research Organization is a leading CRO in the pre-clinical in vivo pharmacology for Alzheimer's Diseases. We help our clients assess in-vivo characteristics, pharmacokinetics, pharmacodynamics and the effects of their experimental treatments against Alzheimer's disease and Taupathies in our proprietary mouse models and have recently expanded to Parkinson's disease and Huntington's disease as well. With our limited focus and extensive know-how, we can provide expertise when designing a study or interpreting results.

We serve a strong and geographically diverse (US, EU, Japan, …) client base in pharma, biotech and academic industry, including the majority of the top 10 pharmaceutical companies worldwide active in Alzheimer’s and the most promising Alzheimer biotechs.

We have provided key data for major Alzheimer's Disease deals over the years as well as provided pivotal in vivo Proof of Concept data for several candidate drugs currently in clinical development. We helped our clients to be the first to demonstrate the synergistic effect of a BACE inhibitor and an aBeta antibody, the effect of Tau antibody on aBeta, the effect of donepezil on brain Abeta,...

The continuous availability of aged mice allows for a short response time and rapid study start.

As we were founded in 2002 as a spin-off from the KU Leuven, we are located in Leuven and are still collaborating with the KU Leuven to further drive innovation within the CRO offering.